TROG 04.01 - Cavilon Breast - TROG Cancer Research

TROG 19.06 DECREASE trial marks recruitment milestone

Read our latest Annual Report highlighting TROG achievements

By w.paterson
14 August, 2021
0 Comments

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Clinical Trial Registration

Registration Link

24 July, 2025

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

LATEST NEWS: 24 July 2025 The inaugural World Radiotherapy

15 July, 2025

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TROG 04.01 – Cavilon Breast

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial